Respiratory Committee Meeting Agenda

Chair(s): Tom Stinchcombe, M.D.
Vice-Chairs: Dennis Wigle (Surgery), Steven Schild (Radiation Oncology), and Stephen Graziano (Correlative Science)

Agenda Items

1. Committee overview and protocol accrual – Chair and Xiaofei Wang
   - Update Alliance Foundation: David Kozono
   - Patient advocate: Pam Moffitt
   - Intergroup trials
     1. NRG LU002: Pranshu Mohindra
     2. EA5152: Muhammad Furqan
     3. S1507: Jimmy Ruiz

2. Stage IV Non-Small Cell Lung Cancer
   - A221504 - Peripheral Opioid Receptor Antagonist in NSCLC – Pankaj Gupta,
     Lyudmila Bazhenova
   - S-1400 SWOG Squamous Master Protocol in Alliance– Lyudmila
     Bazhenova, Tom Stinchcombe
   - ALK Master protocol
   - AFT-09: Chemo-Immunotherapy Sequencing – Tom Hensing
   - AFT-31: Nivolumab +/- abraxane as second line therapy – Neal Ready
   - AFT-42: Nivolumab for patients with compromised organ function – Becca
     Heist, Phil Stella
4. Stage III Non-Small Cell Lung Cancer and Radiation Oncology trials update
   Steven Schild
   ➢ A-31101, RTOG 1306: Personalized therapy for inoperable stage III NSCLC -
     Ramaswamy Govindan
   ➢ ATF-07: Chemoradiation plus veliparib – Tom Stinchcombe
   ➢ AFT-16: Induction PDL-1 inhibition – Helen Ross, Jim Urbanic, David
     Carbone

5. Early Stage Non-Small Cell Lung Cancer and Surgical Studies - Dennis Wigle
   ➢ CALGB 140503: Lobectomy vs. limited resection – Nasser Altorki
   ➢ A151216/081105- ALCHEMIST- Personalized Adjuvant Therapy in Patients
     with Completely Resected Non-Small Cell Lung Cancer – Geoffrey Oxnard,
     Ramaswamy Govindan, Dennis Wigle, Sumithra Mandrekar
   ➢ Chemo-immunotherapy for operable stage III NSCLC Linda Martin

6. Small Cell Lung Cancer
   ➢ CALGB 30610: Limited Stage Intergroup Trial– Jeffrey Bogart and Greg
     Masters
   ➢ SWOG PCI protocol Jyoti Patel
   ➢ Limited stage SCLC ChemoRT +/- atezolizumab concept discussion –
     Helen Ross
   ➢ AFT-17: Pembrolizumab vs topotecan for 2nd line SCLC and update on
     immuno-therapies in SCLC – Tom Stinchcombe

7. Correlative Science- Robert Kratzke, Stephen Graziano
   ➢ Overview of current projects

➢ Joint Alliance SWOG concept: Pembrolizumab in second-line therapy – Hedy Kindler

➢ Other updates – Hedy Kindler, Robert Kratzke

9. Ongoing projects from other committees

➢ CANVAS (AFT-28) - Deborah Schrag

➢ Effect of age and performance status on chemotherapy toxicity over time in patients with advanced non-small cell lung cancer: A Toxicity over Time analysis of CALGB 9730 - Melissa Wong

➢ NCI’s Quantitative Imaging Network U01 - Lawrence Schwartz